Multi-payload antibody-drug conjugates
Callio Therapeutics is a clinical-stage biotechnology company developing next-generation multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. Founded in 2025 and headquartered in Seattle and Singapore, the company's lead program CLIO-8221 is a dual-payload ADC targeting HER2-expressing solid tumors that delivers a topoisomerase 1 inhibitor and an ATR inhibitor simultaneously to overcome resistance to existing ADC therapies.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2025
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
